RenBio

RenBio was thrilled to have Linda Sasset, Andrew Cameron, and Marek Drozdz represent us at the 5th World Congress on Electroporation in Rome, held from September 15-19! During the session on In vivo delivery of genetic medicine through gene electrotransfer, Dr. Linda Sasset delivered an insightful presentation titled: "Enhancing the therapeutic benefits of proteins with short half-lives: delivery of G-CSF and GLP-1 with DNA-based MYO Technology?." We are excited to continue advancing the possibilities of gene electrotransfer and DNA-based therapies. A huge thank you to the organizers and fellow attendees for such a productive event! #Biotechnology #Electroporation #MYOTechnology #RenBio #WorldCongress

We’re hiring a Research Engineer at RenBio! Join our dynamic team where motivated individuals push the boundaries of biotech. If you're eager to innovate in a collaborative environment and become a part of developing an electroporation-based platform technology for next-gen treatments for blood disorders and inflammatory, infectious, and metabolic diseases, apply here! https://lnkd.in/egxaEAbm #ResearchEngineer #BiotechJobs #Electroporation #NYC

As the Global Pandemic Preparedness Summit 2024 gets underway #GPPS2024 CEPI (Coalition for Epidemic Preparedness Innovations) in Rio de Janeiro i'm delighted to anounce $2.9M Wellcome Trust investment in RenBio to develop their antiviral antibody platform! Read here: https://lnkd.in/gRdZmU8H Congratulations to Colleen Loynachan in my team for developing this partnership! Congratulations Rachel Liberatore, PhD and colleagues at RenBio I'm pleased that Wellcome Trust is continuing to invest directly in supporting bold ambitious R&D taking place within biotech companies - science that could save lives in future pandemics; science that takes a leap towards affordable biologics for the world!

RenBio Announces New Awards to Support Continued Development of Its Novel, DNA-Based MYO Technology? Platform for Antiviral Applications https://lnkd.in/gRdZmU8H

RenBio is happy to announce the publication of a recent article in Pharmaceutics, “Enhancing In Vivo Electroporation Efficiency Through Hyaluronidase: Insights into Plasmid Distribution and Optimization Strategies." Led by Senior Research Engineer, Debnath Maji,?we take a look into the promising realm of non-viral plasmid?DNA?delivery through?intramuscular?electroporation?(EP)?and?highlight the role of hyaluronidase in enhancing transfection efficiency.?Hyaluronidase has the?ability to?promote?uniform distribution of plasmid DNA within skeletal muscle, and by?leveraging bioimpedance measurements, we decipher changes induced by hyaluronidase treatment, allowing for further optimization of??EP electrical parameters. This work?underscores?hyaluronidase's potential in augmenting in vivo EP efficacy and offers a roadmap for tailored?EP?strategies. Read the full article?here,?https://lnkd.in/ezUETurk!?

RenBio is seeking a Research Scientist I/II to join our team! Are you interested in cutting-edge technologies and want to change how we fight infectious diseases? If so, this position might be perfect for you. Apply now at https://lnkd.in/g_AG4KfK or share with your network!

Exciting Opportunity at RenBio! Join our innovative team as a Research Associate. We're looking for a highly motivated and goal-oriented individual to contribute to our dynamic and collaborative research environment. If you're passionate about pushing scientific boundaries, fostering innovation, and making a significant impact, we want to hear from you! Apply now at https://lnkd.in/epM_ZQQm or share with your network!

RenBio is thrilled to announce that our?most recent review ,?"Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases,”?is out (https://lnkd.in/e8usgcgs)! Led by Research Associate Carleigh Sussman, it?provides a comprehensive overview of gene therapy's evolution and its pivotal role in modern medicine. It delves into the promise of DNA-based medicines, particularly in managing chronic conditions more effectively. The review explores two key DNA-based gene therapies: adeno-associated virus (AAV)-based gene therapy and plasmid DNA (pDNA)-based gene therapy. It discusses how?both?have shown immense potential in clinical trials, offering robust and durable expression of therapeutic genes with fewer treatments compared to traditional approaches. Moreover, this review sheds light on the use of electroporation (EP) as a method for pDNA delivery. EP has emerged as a promising technique to enhance the efficacy and durability of pDNA-based therapies, paving the way for more efficient treatment strategies for chronic diseases. ?#GeneTherapy #ChronicDiseases #ResearchInnovation

Thrilled to announce that Dr. Rachel Liberatore, PhD and Dr. Linda Sasset are representing RenBio at the ASGCT 27th Annual Meeting in Baltimore! Join us as Dr. Sasset presents her abstract titled "Next-Generation DNA-Based Delivery of Therapeutic Proteins Using MYO Technology: Preclinical Results on Incretins Receptor Agonists" tomorrow at 12:00 PM. Don't miss out on poster #1741! #ASGCT2024 #Biotechnology

RenBio's Dr. Rachel Liberatore, PhD will be at 'AntibodyTherapeutics Xchange 2024' in Philadelphia tomorrow, March 25th through March 27th. Join Dr. Liberatore for a round table discussion on "Novel Delivery Modes for Biologics." We'll explore improving PK, addressing cold chain requirements, and the burden of medical devices. Don't miss out! #AntibodyTherapeutics #BiologicsDelivery #RenBio #Biotechnology https://lnkd.in/eUqXWGMe